BioCentury | Dec 15, 2018
Product Development

O’Day’s expansive task at Gilead

...disease. For example, attempts to build out a cardiovascular franchise after the 2009 acquisition of CV Therapeutics Inc....
...<2%) (B) Myogen Inc. Letairis ambrisentan Ph III complete Pulmonary 2006 $2.5B Mkt; $689M (4%) CV Therapeutics Inc....
BioCentury | Jul 27, 2018
Company News

Milligan, Martin leaving Gilead

...2017, with modest annual growth. Angina drug Ranexa ranolazine, acquired via a 2007 deal for CV Therapeutics Inc....
BioCentury | Jul 26, 2018
Company News

Milligan, Martin leaving Gilead

...2017, with modest annual growth. Angina drug Ranexa ranolazine, acquired via a 2007 deal for CV Therapeutics Inc....
BioCentury | Apr 28, 2017
Emerging Company Profile

Cutting cravings

...The former executive team from CV Therapeutics Inc. are treading familiar ground with an addiction program licensed from...
...and opioid addiction. The compound inhibits aldehyde dehydrogenase 2 family mitochondrial (ALDH2) , a target CV Therapeutics...
BioCentury | Feb 17, 2017
Company News

Gilead, Amygdala deal

...research. GS-6637 was once owned by CV Therapeutics Inc. , which Gilead acquired in 2009. Amygdala said CV Therapeutics...
BioCentury | Feb 16, 2017
Company News

Amygdala acquires addiction candidate from Gilead

...aldehyde dehydrogenase 2 family mitochondrial (ALDH2) inhibitor. Gilead developed GS-6637 based on early work by CV Therapeutics Inc....
BioCentury | Jul 14, 2014
Clinical News

Ranolazine: Phase II data

...500 and 1,000 mg twice daily to treat chronic angina, through its 2009 acquisition of CV Therapeutics Inc....
BioCentury | Aug 5, 2013
Regulation

Rushing to abandon tQT

...TdP risk. One of the best known examples is Ranexa ranolazine, which was developed by CV Therapeutics Inc....
...TdP risk (see BioCentury, Dec. 15, 2003) . Nonetheless, FDA issued an approvable letter to CV Therapeutics...
BioCentury | Apr 15, 2013
Company News

Terrapin management update

...discovery Hired: Michael Wick as EVP of R&D and COO, formerly SVP of research at CV Therapeutics Inc. WIR...
BioCentury | Aug 20, 2012
Clinical News

CPAPP-A* test: Pivotal trial data

...assay in the U.S. and EU, but did not disclose a time frame. In 2007, CV Therapeutics Inc....
...City, Calif.) gained Ranexa, which it markets to treat chronic angina, through its acquisition of CV Therapeutics...
Items per page:
1 - 10 of 554
BioCentury | Dec 15, 2018
Product Development

O’Day’s expansive task at Gilead

...disease. For example, attempts to build out a cardiovascular franchise after the 2009 acquisition of CV Therapeutics Inc....
...<2%) (B) Myogen Inc. Letairis ambrisentan Ph III complete Pulmonary 2006 $2.5B Mkt; $689M (4%) CV Therapeutics Inc....
BioCentury | Jul 27, 2018
Company News

Milligan, Martin leaving Gilead

...2017, with modest annual growth. Angina drug Ranexa ranolazine, acquired via a 2007 deal for CV Therapeutics Inc....
BioCentury | Jul 26, 2018
Company News

Milligan, Martin leaving Gilead

...2017, with modest annual growth. Angina drug Ranexa ranolazine, acquired via a 2007 deal for CV Therapeutics Inc....
BioCentury | Apr 28, 2017
Emerging Company Profile

Cutting cravings

...The former executive team from CV Therapeutics Inc. are treading familiar ground with an addiction program licensed from...
...and opioid addiction. The compound inhibits aldehyde dehydrogenase 2 family mitochondrial (ALDH2) , a target CV Therapeutics...
BioCentury | Feb 17, 2017
Company News

Gilead, Amygdala deal

...research. GS-6637 was once owned by CV Therapeutics Inc. , which Gilead acquired in 2009. Amygdala said CV Therapeutics...
BioCentury | Feb 16, 2017
Company News

Amygdala acquires addiction candidate from Gilead

...aldehyde dehydrogenase 2 family mitochondrial (ALDH2) inhibitor. Gilead developed GS-6637 based on early work by CV Therapeutics Inc....
BioCentury | Jul 14, 2014
Clinical News

Ranolazine: Phase II data

...500 and 1,000 mg twice daily to treat chronic angina, through its 2009 acquisition of CV Therapeutics Inc....
BioCentury | Aug 5, 2013
Regulation

Rushing to abandon tQT

...TdP risk. One of the best known examples is Ranexa ranolazine, which was developed by CV Therapeutics Inc....
...TdP risk (see BioCentury, Dec. 15, 2003) . Nonetheless, FDA issued an approvable letter to CV Therapeutics...
BioCentury | Apr 15, 2013
Company News

Terrapin management update

...discovery Hired: Michael Wick as EVP of R&D and COO, formerly SVP of research at CV Therapeutics Inc. WIR...
BioCentury | Aug 20, 2012
Clinical News

CPAPP-A* test: Pivotal trial data

...assay in the U.S. and EU, but did not disclose a time frame. In 2007, CV Therapeutics Inc....
...City, Calif.) gained Ranexa, which it markets to treat chronic angina, through its acquisition of CV Therapeutics...
Items per page:
1 - 10 of 554